RubberDuckyJJ commented on a stock · Jan 3 16:47

Curis Shares Gain on Results From Leukemia-Treatment Study

Shares of Curis jumped after the company released what it assessed as positive data from a study of its in-development treatment for leukemia.
The stock was up 33%, to $4.07, in midday trading Thursday. Shares ended 2024 down 73%.

The Lexington, Mass., biotech company said its treatment, emavusertib, resulted in 10 objective responses out of 19 response-evaluable patients. Six patients achieved complete remission; two achieved complete remission with either incomplete or partial hematological recovery, meaning that blood cell counts haven't fully returned to normal; and two achieved a morphologic leukemia-free state, which indicates the disappearance of leukemia cells and bone marrow recovery.
Emavusertib previously received orphan drug designation, a regulatory status granted to drugs or biologics intended to treat rare diseases or conditions, from the Food and Drug Administration for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and from the European Commission for the treatment of primary central nervous system lymphoma.
"We continue to be pleased with the monotherapy data in R/R AML patients with a FLT3 mutation and believe these data further support the exciting potential of emavusertib's novel mechanism to address a significant unmet need in patients with AML," Chief Executive James Dentzer said.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more